As elder law attorneys we help many families deal with the legal and financial impact of Alzheimer’s Disease. Over six million Americans now cope with Alzheimer’s, and the numbers are predicted to rise. There is still no cure, but research continues apace and new drugs have been introduced lately. The newest one, Donanemab, was approved by the FDA on July 1, 2024.
Donanemab is an antibody that removes the accumulation of beta-amyloid plaques present in the brain. The drug was developed by Eli Lilly and will be marketed under the name Kisunla. It will be prescribed for those who are in the early stages of the disease or who have only mild cognitive impairment, and whose tests show amyloid involvement. Studies show it can modestly slow down the progression of the disease.
Like Leqembi, approved by the FDA last year, Kisunla is delivered via infusion, Kisunla requires only monthly infusions; Leqembi requires infusions every two weeks. Also, the FDA has said that doctors may consider discontinuing treatment if brain scans show plaque has been sufficiently reduced. As with all amyloid-targeting therapies, possible side effects include brain swelling and micro-bleeds.
It is estimated that a six-month course of Kisunla will cost $12,522. Medicare is expected to cover the treatment, provided the patient meets all the necessary standards to receive the drug. Read more on https://alzheimersnewstoday.com/news/donanemab-approved-early-symptomatic-alzheimers-now-kisunla/
Nursing home care for someone with Alzheimer’s Disease or other chronic, incapacitating diseases can easily take a middle class family broke in no time. For help with eligibility for Medicaid or veterans benefits, call us. We may be able to assist before you lose everything. Call 561-625-1100 to schedule a consultation with our attorneys.
